Free Trial
NASDAQ:OPNT

Opiant Pharmaceuticals (OPNT) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$20.03
$21.10
52-Week Range
N/A
Volume
562,700 shs
Average Volume
77,920 shs
Market Capitalization
$108.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
OPNT stock logo

About Opiant Pharmaceuticals Stock (NASDAQ:OPNT)

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

OPNT Stock News Headlines

Hikma Pharmaceuticals PLC ADR (HKMPY)
Ionis Pharmaceuticals
Kiss of death from Joe Biden
I did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does not care.
Kiss of death from Joe Biden
I did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does not care.
Dechra Pharmaceuticals defies cooling pets market
See More Headlines
Receive OPNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
7/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OPNT
Employees
37
Year Founded
2009

Profitability

Net Income
$3.01 million
Net Margins
-147.90%
Pretax Margin
-147.84%

Debt

Sales & Book Value

Annual Sales
$47.78 million
Book Value
$9.92 per share

Miscellaneous

Free Float
3,865,000
Market Cap
$108.83 million
Optionable
Not Optionable
Beta
0.84

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

OPNT Stock Analysis - Frequently Asked Questions

How were Opiant Pharmaceuticals' earnings last quarter?

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) released its quarterly earnings data on Thursday, November, 11th. The technology company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.41. The technology company had revenue of $16.34 million for the quarter, compared to analyst estimates of $12.45 million. Opiant Pharmaceuticals had a negative trailing twelve-month return on equity of 97.03% and a negative net margin of 147.90%.

What other stocks do shareholders of Opiant Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Opiant Pharmaceuticals investors own include Cara Therapeutics (CARA), AcelRx Pharmaceuticals (ACRX), Sangamo Therapeutics (SGMO), Synchrony Financial (SYF), Vodafone Group Public (VOD), Agenus (AGEN) and Aldeyra Therapeutics (ALDX).

This page (NASDAQ:OPNT) was last updated on 7/21/2024 by MarketBeat.com Staff

From Our Partners